RHOA and obesity due to melanocortin 4 receptor deficiency: As shown in rodent models (Zhang et al., 2018), selective targeting RhoA/ROCK signaling in lacteals of the small intestine is clinically of significance to a novel therapeutic approach for the treatment of obesity and metabolic dysfunction.